CA1158978A - Process for obtaining lipid envelope virus subunits, notably antigens for use as vaccines, the products obtained and their applications - Google Patents
Process for obtaining lipid envelope virus subunits, notably antigens for use as vaccines, the products obtained and their applicationsInfo
- Publication number
- CA1158978A CA1158978A CA000358547A CA358547A CA1158978A CA 1158978 A CA1158978 A CA 1158978A CA 000358547 A CA000358547 A CA 000358547A CA 358547 A CA358547 A CA 358547A CA 1158978 A CA1158978 A CA 1158978A
- Authority
- CA
- Canada
- Prior art keywords
- antigens
- virus
- chloroform
- subunits
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 64
- 239000000427 antigen Substances 0.000 title claims abstract description 50
- 102000036639 antigens Human genes 0.000 title claims abstract description 50
- 108091007433 antigens Proteins 0.000 title claims abstract description 50
- 241000700605 Viruses Species 0.000 title claims abstract description 45
- 210000004779 membrane envelope Anatomy 0.000 title claims abstract description 12
- 229960005486 vaccine Drugs 0.000 title abstract description 37
- 238000002360 preparation method Methods 0.000 claims abstract description 44
- 239000003599 detergent Substances 0.000 claims abstract description 38
- 210000002845 virion Anatomy 0.000 claims abstract description 31
- 239000000725 suspension Substances 0.000 claims abstract description 17
- 229960003971 influenza vaccine Drugs 0.000 claims abstract description 12
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 230000007935 neutral effect Effects 0.000 claims abstract description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 74
- 241000712461 unidentified influenza virus Species 0.000 claims description 29
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 16
- 229920000053 polysorbate 80 Polymers 0.000 claims description 16
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 14
- 229940068968 polysorbate 80 Drugs 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 10
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- -1 hexitol anhydrides Chemical class 0.000 claims description 9
- 230000002779 inactivation Effects 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 7
- 238000002270 exclusion chromatography Methods 0.000 claims description 6
- 229960000380 propiolactone Drugs 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical group O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 238000005352 clarification Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 239000012429 reaction media Substances 0.000 abstract description 8
- 150000008282 halocarbons Chemical class 0.000 abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 102000005348 Neuraminidase Human genes 0.000 description 21
- 108010006232 Neuraminidase Proteins 0.000 description 21
- 239000012528 membrane Substances 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000000601 reactogenic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000206607 Porphyra umbilicalis Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000002161 passivation Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 241000148815 Leucozonella rubens Species 0.000 description 1
- 108010004718 Lipoglycopeptides Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150079778 PREP gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8002978A FR2475572A1 (fr) | 1980-02-11 | 1980-02-11 | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
| FR8002.978 | 1980-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1158978A true CA1158978A (en) | 1983-12-20 |
Family
ID=9238454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000358547A Expired CA1158978A (en) | 1980-02-11 | 1980-08-19 | Process for obtaining lipid envelope virus subunits, notably antigens for use as vaccines, the products obtained and their applications |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4522809A (https=) |
| CA (1) | CA1158978A (https=) |
| FR (1) | FR2475572A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988008718A1 (en) * | 1987-05-05 | 1988-11-17 | Molecular Engineering Associates, Inc. | Intranasal immunization against viral infection using viral glycoprotein subunit vaccine |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2475572A1 (fr) * | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
| JPS63501121A (ja) * | 1985-08-15 | 1988-04-28 | アムジエン | 酵母細胞からｂ型肝炎表面抗原を抽出するための細胞溶解法および緩衝液 |
| US4790987A (en) * | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
| US4789545A (en) * | 1986-03-31 | 1988-12-06 | New York Blood Center, Inc. | Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof |
| DK0431129T3 (da) * | 1989-06-15 | 1996-06-17 | Rorer Int Overseas | Fremgangsmåder til inaktivering af virus i viruskontaminerede farmaceutiske præparater |
| US5236840A (en) * | 1990-01-18 | 1993-08-17 | University Of Hawaii | Method for growing crustacean virus in fish cells |
| FR2674536B1 (fr) * | 1991-03-29 | 1994-10-21 | Fondation Nale Transfusion San | Procede d'inactivation de virus et composition pharmaceutique pour l'inactivation de virus. |
| FR2723740B1 (fr) * | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
| AUPN030794A0 (en) | 1994-12-22 | 1995-01-27 | Aruba International Pty Ltd | Discontinuous plasma or serum delipidation |
| US7407663B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
| US20090017069A1 (en) * | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
| US7407662B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
| AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
| US7439052B2 (en) * | 2000-06-29 | 2008-10-21 | Lipid Sciences | Method of making modified immunodeficiency virus particles |
| CZ2003930A3 (cs) * | 2000-10-02 | 2003-08-13 | Glaxosmithkline Biologicals S. A. | Vakcinační prostředek obsahující štěpený virus s obalem |
| EP1409108A4 (en) * | 2001-06-25 | 2007-11-14 | Lipid Sciences Inc | HOLLOW FIBER CONTACTOR SYSTEMS FOR THE REMOVAL OF LIPIDS FROM LIQUIDS |
| EP1412045A4 (en) * | 2001-06-25 | 2007-05-02 | Lipid Sciences Inc | A SOLVENT FOR REMOVING LIPIDES FROM FLUIDS USING SYSTEMS AND METHOD |
| US7033500B2 (en) * | 2001-06-25 | 2006-04-25 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
| US20060060520A1 (en) * | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
| US6991727B2 (en) * | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
| US20040106556A1 (en) * | 2002-08-26 | 2004-06-03 | Yanhong Zhu | Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles |
| US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| CA2531227A1 (en) * | 2003-07-03 | 2005-02-10 | Lipid Sciences Inc. | Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
| US6960803B2 (en) * | 2003-10-23 | 2005-11-01 | Silicon Storage Technology, Inc. | Landing pad for use as a contact to a conductive spacer |
| EP1982727A1 (en) * | 2007-04-17 | 2008-10-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for purification of viral proteins |
| EP2192917B1 (en) * | 2007-08-28 | 2014-01-29 | Baxter International Inc. | Method for producing viral vaccines |
| BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
| AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| CA3083194A1 (en) | 2017-11-22 | 2019-05-31 | Hdl Therapeutics, Inc. | Systems and methods for priming fluid circuits of a plasma processing system |
| AU2018396009A1 (en) | 2017-12-28 | 2020-07-16 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
| CN111629751B (zh) | 2018-01-22 | 2025-02-21 | 美国政府(由卫生和人类服务部的部长所代表) | 广泛保护性灭活流感病毒疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE661402A (https=) * | 1964-03-20 | |||
| US3847737A (en) * | 1965-03-22 | 1974-11-12 | A Kanarek | Inactivation of myxoviruses and method of preparing a vaccine therefrom |
| US3639578A (en) * | 1970-02-18 | 1972-02-01 | Int Minerals & Chem Corp | Virus insecticide |
| GB1486557A (en) * | 1973-10-18 | 1977-09-21 | Flockhart & Co | Process for the preparation of pyrogen-free sub-unit vaccine |
| FR2422720A2 (fr) * | 1977-04-26 | 1979-11-09 | Elf Aquitaine | Separation et purification de proteines par chromatographie |
| FR2475572A1 (fr) * | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
-
1980
- 1980-02-11 FR FR8002978A patent/FR2475572A1/fr active Granted
- 1980-08-19 CA CA000358547A patent/CA1158978A/en not_active Expired
-
1984
- 1984-08-01 US US06/636,791 patent/US4522809A/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988008718A1 (en) * | 1987-05-05 | 1988-11-17 | Molecular Engineering Associates, Inc. | Intranasal immunization against viral infection using viral glycoprotein subunit vaccine |
| AU623857B2 (en) * | 1987-05-05 | 1992-05-28 | Molecular Engineering Associates, Inc. | Intranasal immunization against viral infection using viral glycoprotein subunit vaccine |
| US5427782A (en) * | 1987-05-05 | 1995-06-27 | Molecular Engineering Associates, Inc. | Intranasal immunization against viral infection using viral glycoprotein subunit vaccine |
| US5843451A (en) * | 1987-05-05 | 1998-12-01 | Vaxcel, Inc. | Intranasal immunization against viral infection using viral glycoprotein subunit vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2475572A1 (fr) | 1981-08-14 |
| US4522809A (en) | 1985-06-11 |
| FR2475572B1 (https=) | 1982-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1158978A (en) | Process for obtaining lipid envelope virus subunits, notably antigens for use as vaccines, the products obtained and their applications | |
| KR100871021B1 (ko) | 인플루엔자 백신 조성물 | |
| CA2197683C (en) | Method for preparing an influenza virus, antigens obtained and applications thereof | |
| CA2386014C (en) | Influenza vaccine | |
| DE69229703T2 (de) | Wiederhergestellte Influenza-Virosomen mit immunostimulierenden und immunoverstärkenden Eigenschaften und diese enthaltende Impfstoffe | |
| US10398771B2 (en) | Process for producing influenza vaccine | |
| JP2011515387A (ja) | インフルエンザウイルスワクチン抗原の調製における改良 | |
| RU2710239C1 (ru) | Способ получения антигена или антигенов для производства противогриппозной вакцины и вакцина на его основе | |
| JP2002532435A (ja) | Ｒｓｖサブユニット成分およびインフルエンザウイルス調製物を含む多価免疫原性組成物 | |
| HUE031593T2 (en) | New vaccine preparation for flu | |
| JP5843615B2 (ja) | 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製 | |
| WO2011154976A2 (en) | Improved influenza vaccine | |
| CN117618548A (zh) | 一种rsv疫苗组合物及其制备方法和应用 | |
| CN117323427A (zh) | 脂质体佐剂及其制造方法和应用 | |
| DE3005495C2 (de) | Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen | |
| EP3858380A1 (en) | Inactivated whole-virus influenza vaccine and method for preparing same | |
| RU2804948C2 (ru) | Пентавалентная субъединичная вакцина против респираторных инфекций и способ ее получения | |
| Berezin et al. | Isolation and studies of myxovirus glycoproteins | |
| Noori et al. | Construction of Influenza A/H1N1 virosomal nanobioparticles | |
| WO2009102229A1 (ru) | Липид-протеиновый рафтовый комплекс из оболочки вируса гриппа а для противогриппозных вакцин и способ его выделения, способ получения вирусоподобных частиц из таких комплексов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |